Hans Keirstead
Company: AiVita Biomedical
Job title: Chief Executive Officer
Seminars:
Developing a Patient Specific Dendritic Cell Immunotherapy that Shows Effective Patinet Response 9:00 am
Developing a personal, precision medicine that minimizes adverse events and maximizes efficacy Employing a pan-antigenic approach to protect against mutation-associated loss of function for more powerful therapeutics vaccines Diving into promising data from cancer trials includes safety, induction of immune responses, tumor regressions, and increased progression free and overall survival of patientsRead more
day: Conference Day One
Panel Discussion:Examining the Route of Personalized Cancer Vaccines From a Range of Modalities Through the Clinic to Get Effective Therapies to Patients Faster 9:30 am
Uncovering how successful trials are in selecting patients and achieving clinical efficacy Understanding the importance of durability and half-life of vaccines in patients for a swift journey through the clinic Navigating the regulatory frameworks for personalized medicine to ensure success post-approvalRead more
day: Conference Day Two